Survey: Sustained-release dexamethasone insert earns high satisfaction rating from cataract patients
Subjective quality assessment of a sustained-release dexamethasone intracanalicular insert showed a high degree of patient satisfaction regarding comfort, convenience and pain control.
The insert, Dextenza by Ocular Therapeutix, was used as an alternative to postoperative topical corticosteroids in two phase 3 randomized, controlled, multicenter trials in patients undergoing cataract surgery. Efficacy in reducing inflammation and postoperative pain was demonstrated.
After completion of the study, 25 patients were selected from four of the 32 study sites and interviewed on the telephone for approximately 45 minutes on their overall experience with the insert.
A high level of satisfaction was reported by 92% of the patients. All patients described the insert as comfortable, and most of them said they were not aware of it being in the eye. All but one found the insert more convenient as compared with eye drops, and 88% reported they were very satisfied with relief from symptoms experienced after cataract surgery. Most patients said they would recommend the insert to family and friends and would request it if they were to undergo cataract surgery again, even if they had to pay an extra cost.
According to the authors, “The absence of preservatives in the product may also act to improve comfort, especially in patients who compared their use of the dexamethasone insert with prior drop experience, as the majority of topical corticosteroid formulations are not preservative free.”
The immediate initiation of therapy at the completion of cataract surgery may also account for the rapid and sustained effect on postoperative pain. – by Michela Cimberle
Disclosure: Gira reported he received a grant to complete this research but has no other proprietary interests. Please see the study for all other authors’ relevant financial disclosures.